S. C. Dollard, S. D. Grosse, and D. S. Ross, New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection, Rev Med Virol, vol.17, issue.5, pp.355-63, 2007.

M. Leruez-ville and Y. Ville, Fetal cytomegalovirus infection, Best Pract Res Clin Obstet Gynaecol. janv, vol.38, pp.97-107, 2017.

M. Leruez-ville, I. Ghout, L. Bussières, J. Stirnemann, J. Magny et al., In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase II study, Am J Obstet Gynecol, vol.215, issue.4, pp.462-463, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02641581

K. M. Stone, R. Reiff-eldridge, A. D. White, J. F. Cordero, Z. Brown et al., Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999, Birth Defects Res A Clin Mol Teratol. avr, vol.70, issue.4, pp.201-208, 2004.

P. Ceccald, L. Mandelbrot, R. Farinotti, F. Forestier, and S. Gil, Contributions of the ex vivo human perfused placenta in the study of placental transfer of drugs, J Gyné cologie Obstétrique Biol Reprod. dé c, vol.39, issue.8, pp.601-606, 2010.

J. C. Challier, Criteria for evaluating perfusion experiments and presentation of results, Contrib Gynecol Obstet, vol.13, pp.32-41, 1985.

H. Schneider, M. Panigel, and J. Dancis, Transfer across the perfused human placenta of antipyrine, sodium and leucine, Am J Obstet Gynecol, vol.15, issue.6, p.4676572, 1972.

, PREVYMIS (letermovir) Tablets and PREVYMIS (letermovir) Injection

D. Kropeit, J. Scheuenpflug, K. Erb-zohar, A. Halabi, H. Stobernack et al., Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment, Br J Clin Pharmacol. sept, vol.83, issue.9, pp.1944-53, 2017.

D. P. Melendez and R. R. Razonable, Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infection and Drug Resistance, 2015.

P. Lischka, G. Hewlett, T. Wunberg, J. Baumeister, D. Paulsen et al., Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246, vol.54, pp.1290-1297, 20047911.

F. M. Marty, P. Ljungman, R. F. Chemaly, J. Maertens, S. S. Dadwal et al., Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation, N Engl J Med, vol.21, issue.25, pp.2433-2477, 2017.

L. K. Dropulic and J. I. Cohen, Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections, Clin Pharmacol Ther, vol.88, issue.5, pp.610-619, 2010.

G. W. Koszalka, N. W. Johnson, S. S. Good, L. Boyd, S. C. Chamberlain et al., Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication, Antimicrob Agents Chemother. 8 janv, vol.46, issue.8, pp.2373-80, 2002.

, Efficacy and Safety Study of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir -Full Text View-ClinicalTrials

, Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients-Full Text View-ClinicalTrials, p.19

D. Evain-brion, P. Berveiller, and S. Gil, Placental transfer of drugs, Therapie. fé vr, vol.69, issue.1, pp.3-11, 2014.

P. Myllynen and K. Vähä, Placental transfer and metabolism: An overview of the experimental models utilizing human placental tissue, Toxicol In Vitro [Internet]. fé vr, vol.27, issue.1, pp.507-519, 2013.

L. Mandelbrot, D. Duro, E. Belissa, and G. Peytavin, Placental Transfer of Rilpivirine in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob Agents Chemother. 5 janv, vol.59, issue.5, pp.2901-2904, 2015.

L. Gavard, S. Gil, G. Peytavin, P. Ceccaldi, C. Ferreira et al., Placental transfer of lopinavir/ ritonavir in the ex vivo human cotyledon perfusion model, Am J Obstet Gynecol. juill, vol.195, issue.1, pp.296-301, 2006.

V. Faure-bardon, L. Mandelbrot, D. Duro, C. Dussaux, M. Le et al., Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model, AIDS Lond Engl. 28 janv, vol.32, issue.3, pp.321-326, 2018.

P. Bapat, L. Pinto, A. Lubetsky, H. Berger, and G. Koren, Rivaroxaban transfer across the dually perfused isolated human placental cotyledon, Am J Obstet Gynecol, vol.213, issue.5, pp.710-711, 2015.

B. Krauer, P. Dayer, and R. Anner, Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs, Br J Obstet Gynaecol. sept, vol.91, issue.9, p.6477846, 1984.

J. A. Ring, H. Ghabrial, M. S. Ching, R. A. Smallwood, and D. J. Morgan, Fetal hepatic drug elimination, Pharmacol Ther. dé c, vol.84, issue.3, pp.46-53, 1999.

G. Koren, G. Klinger, and A. Ohlsson, Fetal Pharmacotherapy. Drugs. 1 avr, vol.62, issue.5, pp.757-73, 2002.

C. Vinot, J. Tréluyer, G. C. Gavard, L. Peytavin, G. Mandelbrot et al., Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model, Antimicrob Agents Chemother. 1 mai, vol.60, issue.5, pp.3112-3116, 2016.

L. Mandelbrot, D. Duro, E. Belissa, and G. Peytavin, Placental transfer of darunavir in an ex vivo human cotyledon perfusion model, Antimicrob Agents Chemother. sept, vol.58, issue.9, pp.5617-5637, 2014.

P. Berveiller, O. Mir, C. Vinot, C. Bonati, P. Duchene et al., Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model, Am J Obstet Gynecol. 1 janv, vol.206, issue.1, pp.92-93, 2012.

, CRAT-Centre de ré fé rence sur les agents tératogènes chez la femme enceinte

L. Mathiesen, T. Mose, T. J. Mørck, J. Nielsen, L. K. Nielsen et al., Quality assessment of a placental perfusion protocol, Reprod Toxicol. 1 aoû t, vol.30, issue.1, pp.138-184, 2010.

P. Berveiller, S. Gil, and F. Vialard, Placental perfusion: interest and limits, J Matern Fetal Neonatal Med. 3 juin, vol.30, issue.11, pp.1347-1355, 2017.